在CDK4/6抑制剂治疗下转移性乳腺癌中,蒂米丁激酶1度和活性
Stefanos Ioannis Moukas1, Merle Dohn2, Catrin Lehnerdt3
1Department of Gynecology and Obstetrics, University Hospital Essen, Hufelandstrasse 55, 45147, Essen, Germany. stefanos.moukas@uk-essen.de.
Scientific reports
|March 26, 2025
概括
血液中的提米丁激酶1 (TK1) 水平可能有助于管理激素受体阳性转移性乳腺癌的治疗. 基线高的TK1和治疗期间的变化与接受CDK4/6抑制剂的患者的较差结果相关.
科学领域:
- 在瘤学瘤学.
- 生物化学 生化学
- 翻译研究是翻译研究.
背景情况:
- 激素受体阳性 (HR+),HER2阴性 (HER2-) 转移性乳腺癌 (mBC) 需要有效的治疗管理.
- 结合内分泌疗法 (ET) 的CDK4/6抑制剂 (CDK4/6i) 是标准的治疗方法.
- 生物标志物是指导和监测mBC治疗疗效的必要条件.
研究的目的:
- 研究胺基酶1 (TK1) 度和活性作为治疗管理的生物标志物的潜力.
- 评估HR+/HER2-mBC患者中TK1的价值,这些患者接受了CDK4/6i和/或ET治疗.
- 为了将基线和治疗期间的TK1水平与治疗结果相关联,包括无进展生存期 (PFS).
主要方法:
- 在基线和治疗期间从110名HR+/HER2-mBC患者收集了血液样本.
- 测量了TK1度和活性.
- 分析了TK1水平,治疗反应和PFS之间的相关性,特别是在CDK4/6i队列中.
主要成果:
- 在匹配样本中,TK1度和活性没有显著的相关性.
- 高基线TK1度和活性与降低PFS和对CDK4/6i的初级耐药性有关.
- 在CDK4/6i治疗期间TK1活性升高和TK1度增加与PFS降低相关.
结论:
- 在HR+/HER2-mBC中,TK1度和活性显示出CDK4/6i治疗的预测生物标志物的潜力.
- 在治疗前和治疗期间监测TK1水平可能有助于指导治疗决策.
- 需要进一步的研究来确定TK1在临床实践中对mBC管理的作用.
关键词:
乳腺癌 乳腺癌 乳腺癌纵向研究是指长度研究.新生体转移的转移.在Palbocicliblib中使用.精准医学是一门精准的医学.预测 预后 预测 预测没有进展的生存率.里博西克利布 (Ribociclib) 是一种可靠的药物.提米丁基因酶 1 的作用.更多相关视频
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
7.2K
08:48An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation
Published on: June 30, 2015
8.2K
相关概念视频
02:34Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
02:57Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
02:15M-Cdk Drives Transition Into Mitosis
5.5K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.5K